TR146 Cell Line

Tool Details

*FOR RESEARCH USE ONLY

• Name: TR146 Cell Line
• Alternate name: Tr146; TR-146; TR 146
• Organism: Human
• Gender: Female
• Tissue: Buccal mucosa that had infiltrated a lymph node
• Donor: 67 year old female patient with previous radiotherapy (6,000 rads) and neck dissection
• Disease: Cancer
• Growth properties: Adherent
• Model: Tumourigenic line
• Model description: TR146 cell ine is tumourigenic in female (nu/nu) mice resulting in the production of rapidly progressing tumours
• Crispr: No
• Conditional: Yes
• Description: Derived from well-differentiated keratinizing squamous cell carcinoma of the buccal mucosa the TR146 cell line represents an in vitro model to study permeability, absorption and metabolism of various enzymatically labile drugs and substances including epithelial-mesenchymal transition (EMT) markers, tight junction proteins and aquaporins. Due to morphological similarities and comparable permeability, excised porcine buccal mucosa has been considered a reasonably good model of human buccal mucosa for drug delivery studies. However, for rapid and efficient screening of drug permeability, a cell line generally holds advantages over in vitro models of excised tissue. Closely resembling normal human buccal epithelium, the cell line functions as a reliable oral mucosa model. TR146 has been characterised for permeability of a number of substances of varying molecular weight and hydrophilicity over a range of pH and osmolality. Activity of aminopeptidase, carboxypeptidase and esterase has also been studied and shown to be comparable with that of human buccal epithelium.
• Application: Human buccal mucosa modeling; Permeability, absorption and metabolism studies of various substances and enzymatically labile drugs; Drug delivery studies
• Production details: The TR146 cell line originates from a human neck metastasis of a buccal carcinoma, derived from neck node (primary tumour sited in buccal mucosa). Well-differentiated. Female patient, 67 years. Previous radiotherapy (6,000 rads) and neck dissection
• Biosafety level: 2
• Additional notes: Histology: well-differentiated keratinizing squamous cell carcinoma. Cell type: polygonal
• Cellosaurus id: CVCL_2736

Applications

• Application: Human buccal mucosa modeling; Permeability, absorption and metabolism studies of various substances and enzymatically labile drugs; Drug delivery studies
• Application notes: Transport studies involving C-reactive protein; Barrier function assessments using transepithelial electrical resistance and carboxyfluorescein permeability assays; Cytotoxicity studies with antibacterial compounds; Viability and metabolic activity investigations post blue laser light exposure; Candida albicans infection studies; Insulin permeability studies

Handling

• Format: Frozen
• Volume: 1 ml
• Growth medium: HAMS F12 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)
• Temperature: 37° C
• Atmosphere: 5% CO2
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice
• Storage conditions: Liquid Nitrogen
• Subculture routine: Split sub-confluent cultures (70-80%) seeding at approximately 1-2 x 104 cells/cm2 using 0.05% trypsin or trypsin/EDTA; 5% CO2; 37C. Cells can reach a maximum density of 7 x 104 cells/cm2
• Mycoplasma free: Yes
• Str profiling: Amelogenin: X; CSF1PO: 11,13; D13S317: 11,14; D16S539: 13; D5S818: 10,11; D7S820: 10,12; THO1: 9; TPOX: 8,9; vWA: 15,18

References

• Lin et. al. 2021. Pharmaceutics 13(2):256. PMID: 33673378
• Mogavero and Hube. 2021. Methods Mol Biol 2260:133-143. PMID: 33405035
• Lin et. al. 2020. Tissue Barriers 8(2): 1784644. PMID: 32614652
• Rupel et.al. 2019. NPJ Biofilms Microbiomes. 5: 29. PMID: 31602310
• Laurén et.al. 2018. Pharm Res. 22,35(7):145. PMID 29790010
• Kalu et al. 2017. Oncotarget. 8(49):86369-86383. PMID: 29156801
• Li et al. 2017. Cancer Cell. 31(2):225-239. PMID: 28196595
• Pistone et al. 2016. Eur J Pharm Sci. 96:381-389. PMID: 27721043
• Nilsen et al. 2016. Eur J Oral Sci. :. PMID: 27711994
• Iyire et al. 2016. Sci Rep. 6:32498. PMID: 27581177
• Goyer et al. 2016. PLoS One. 11(3):e0149159. PMID: 26933885
• Hyakusoku et al. 2016. J Exp Clin Cancer Res. 35:6. PMID: 26754630
• Zeng et al. 2015. Int J Pharm. 495(2):1028-37. PMID: 26403384
• De Ryck et al. 2015. AMB Express. 5:27. PMID: 25995981
• O'Callaghan et al. 2015. Mol Med Rep. :. PMID: 26005189
• Chai et al. 2012. J R Soc Interface. 9(77):3528-38. PMID: 22915635
• Mrck Nielsen et al. 2000. Int J Pharm. 200(2):261-70. PMID: 10867256
• Nielsen et al. 2000. Int J Pharm. 194(2):155-67. PMID: 10692640
• Jacobsen et al. 1999. Eur J Pharm Biopharm. 48(3):217-24. PMID: 10612032
• Nielsen et al. 1999. Int J Pharm. 185(2):215-25. PMID: 10460917
• Nielsen et al. 1999. J Control Release. 60(2-3):223-33. PMID: 10425328
• Pedersen et al. 1999. Drug Dev Ind Pharm. 25(4):463-70. PMID: 10194601
• Jacobsen et al. 1999. Eur J Oral Sci. 107(2):138-46. PMID: 10232463
• Rupniak et al. 1985. J Natl Cancer Inst. 75(4):621-35. PMID: 2413234